Vedolizumab in early and late Crohn's disease: a phase 4 open-label cohort study.
D'Haens GR, et al. Vedolizumab in early and late Crohn's disease: a phase 4 open-label cohort study (LOVE-CD). Lancet Gastroenterol Hepatol. 2026;11(1):12–21.
*No open access
EVOLVE - Published Article
Bressler B et al. Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naive Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021;15(10):1694-1706
*Open access
EVOLVE Expansion - Published Article
Christensen B, et al. Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Early or Late Crohn's Disease: Results From the EVOLVE Expansion Study. Crohns Colitis 360. 2025 Jul 9;7(3)
*Open access
EVOLVE Expansion – Disease location - Published Article
Scharl M, et al. Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease By Disease Location: Results from the EVOLVE Expansion Study. J Clin Gastroenterol. 2025 Jun 20.
*Open access
Disease Clearance in UC: A Narrative Review - Published Article
Danese S, et al. Disease Clearance in Ulcerative Colitis: A Narrative Review. United European Gastroenterology Journal, 2025; 13:902–910
*Open access
GEMINI 1 - Published article
Feagan BG et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2013;369:699-710. doi:10.1056/NEJMoa1215734
*Open access
GEMINI 2 - Published article
Sandborn WJ et al. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2013;369(8):711-721. doi:10.1056/NEJMoa1215739
*Open access
GEMINI LTS - Published Article
Loftus EV Jr et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353-1365. doi:10.1111/apt.16060
*Open access
VARSITY - Published Article
Sands BE et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med 2019;381:1215-1226. doi:10.1056/NEJMoa1905725
*Open access
EARNEST - Published Article
Travis S et al. Vedolizumab for the Treatment of Chronic Pouchitis. N Engl J Med 2023;388:1191-1200. doi:10.1056/NEJMoa2208450
*Open access
PRIVEDO - Published Article
PRIVEDO - an investigator-initiated study Macaluso FS, Fries W, Viola A, et al. Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study
*No open access
VISIBLE 1 - Published Article
Sandborn WJ et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572.e12.doi:10.1053/j.gastro.2019.08.027
*Open access
VISIBLE 2 - Published Article
Vermeire S et al. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2022;16(1):27-38. doi:10.1093/ecco-jcc/jjab133
*Open access